Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

New England Journal of Medicine

Volumn 348, Issue 22, 2003, Pages 2175-2185

  Lalezari, Jacob P ^a,m   Henry, Keith ^b   O'Hearn, Mary ^c   Montaner, Julio S G ^d   Piliero, Peter J ^e   Trottier, Benôit ^f   Walmsley, Sharon ^g   Cohen, Calvin ^h   Kuritzkes, Daniel R ⁱ   Eron Jr , Joseph J ^j   Chung, Jain ^k   DeMasi, Ralph ^l   Donatacci, Lucille ^k   Drobnes, Claude ^l   Delehanty, John ^l   Salgo, Miklos ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e ALBANY MEDICAL COLLEGE   (United States)

^f Clinique Médicale I'Actuel   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h Boston Community Research Initiative of New England   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^k HOFFMANN LA ROCHE INC   (United States)

^l Trimeris Pharmaceuticals   (United States)

^m Quest Clinical Research   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANALGESIC AGENT; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; T 1249; TENOFOVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANOREXIA; ARTICLE; BLOOD SAMPLING; BRAZIL; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLATULENCE; GENOTYPE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INJECTION SITE; INSOMNIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEXICO; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; REGRESSION ANALYSIS; RESPIRATORY DISTRESS; SKIN CYST; SKIN INDURATION; SKIN NODULE; T LYMPHOCYTE; TREATMENT OUTCOME; UNITED STATES; VIRUS LOAD; VOMITING; WEIGHT REDUCTION;

ADULT; ANTI-HIV AGENTS; BRAZIL; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; NORTH AMERICA; PATIENT COMPLIANCE; PEPTIDE FRAGMENTS; RNA, VIRAL;

EID: 0038576281     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa035026     Document Type: Article

References (19)

1. Hoetelmans RM. Sanctuary sites in HIV-1 infection. Antivir Ther 1998;3:Suppl 4:13-7.
2. Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002;3:27-35.
3. Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy: the ATHENA cohort. AIDS 2002;16:737-45.
4. Moyle G, Carr A. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. HIV Clin Trials 2002;3:89-98.
5. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
6. Casado JL, Sabido R, Perez-Elias MJ, et al. Percentage of adherence correlates with the risk of protease inhibitor treatment failure in HIV-infected patients. Antivir Ther 1999;4:157-61.
7. Raboud JM, Harris M, Rae S, Montaner JS. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med 2002;3:118-24.
8. Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999;13:2061-8.
9. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000;44:2109-17.
10. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9:1051-3.
11. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4:1302-7.
12. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and anti-viral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002;18:685-93. [Erratum, AIDS Res Hum Retroviruses 2003;19:83.]
13. Lalezari JP, DeJesus E, Northfelt DW, et al. A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir, and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antiviral Ther (in press).
14. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003;17:691-8.
15. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95.
16. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000;5:41-8.
17. AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences. Rockville, Md.: Division of AIDS, National Institute of Allergy and Infectious Diseases, 1996.
18. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics 1996;52:1324-33.
19. Le Corfec E, Chevret S, Costagliola D. Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics. Stat Med 1999;18:1803-17.